Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

U.S.-Made Compounded Oral Treatment for Feline Infectious Peritonitis Now Available


News provided by

Stokes Healthcare

May 21, 2024, 13:15 ET

Share this article

Share toX

Share this article

Share toX

Stokes Pharmacy and Bova exclusive partnership.
Stokes Pharmacy and Bova exclusive partnership.

Stokes Pharmacy, a leading veterinary compounding pharmacy, announces an exclusive partnership with the Bova Group to offer a U.S.-made oral treatment for FIP, or Feline Infectious Peritonitis. Compounded GS-441524 will be available June 1 by veterinary prescription for individual patients and for veterinary office use in permitted states. For more information, go to stokespharmacy.com/fip.

MOUNT LAUREL, N.J., May 21, 2024 /PRNewswire-PRWeb/ -- Stokes Pharmacy, a leading veterinary compounding pharmacy, announces an exclusive partnership with the Bova Group to offer a U.S.-made oral treatment for FIP, or Feline Infectious Peritonitis. Veterinarians will now be able to manage this once-fatal virus with Stokes Pharmacy's compounded preparation, which is supported by Bova's unique drug formula that has been utilized in clinical research studies across the globe and is currently in use by Bova Aus and Bova UK, with exports to other countries with import permissions in place.

Previous attempts to treat FIP involved medications like prednisolone, interferon, and polyprenyl immunostimulant. These treatments were largely unsuccessful, often resulting in euthanasia. GS-441524 tablets are now available in a quad-scored, 50 mg tuna-flavored tablet with dosages that address FIP diagnoses, including:

Stokes Pharmacy, a leading veterinary compounding pharmacy, announces an exclusive partnership with the Bova Group to offer a U.S.-made oral treatment for FIP, or Feline Infectious Peritonitis.

Post this
  • With effusions but without any ocular or neurological involvement (wet FIP)
  • No effusion and without ocular or neurological signs (dry FIP)
  • With ocular signs (no neurological involvement)
  • With neurological signs

Stokes' president, Michael Tursi, states, "Made possible by our Bova partnership, Stokes Pharmacy will compound and sell the only oral formula identical to the Bova formula used in clinical studies across the globe. Our tablets were tested by Bova to meet their exact specifications. We are thrilled to bring this long-awaited treatment to the United States and put FIP treatment back in the hands of the veterinarians."

With no legal access to oral FIP treatment available in the U.S., veterinarians and pet owners have previously relied on options sourced outside a pharmacy or FDA-registered manufacturer. Bova, recognizing this gap in veterinary medicine, vetted industry leaders to find the right partner to bring their formula to the U.S. market. Stokes' and Bova's shared commitment to raising the standard of care in animal health through high-quality medications is the foundation of this exclusive partnership.

Bova's Managing Director, Nick Bova, states, "The introduction of FIP products to Australia and subsequently to the UK has led us on a transformative path. Collaborating with Feline Specialists around the world has propelled the progression of knowledge and comprehension of FIP. At Bova, we have been fortunate enough to support multiple clinical trials around the world on our unique formulation. This has helped give veterinarians confidence in using our formula and bringing the treatment of this fatal disease back under their control. There are so many black-market options available out there and their quality is so varied. We wanted a partner who took quality and science as seriously as we do at Bova. Stokes Pharmacy is an impressive organization that prioritizes quality and science. Now, together, we can finally help save cats' lives across the USA who are impacted by this terrible disease."

FDA's Center for Veterinary Medicine (CVM) has notified veterinarians that compounded GS-441524 falls under Guidance for Industry #256 and is allowed to be compounded and legally prescribed. Stokes has nominated GS to be included on the animal drug bulk substances list regarding GFI #256 office use and it is now on the GFI under review list. This means that GS-441524 50 mg tablets can be sold to hospitals for office use in all states except Arkansas, Maine, Massachusetts, New Mexico, New York, Oregon, Rhode Island, and West Virginia. Veterinarians who work in a state that does not allow compounded medications for office use can prescribe the drug in a patient's name.

Compounded GS-441524 will be available June 1 by veterinary prescription for individual patients and for veterinary office use in permitted states. For more information, go to stokespharmacy.com/fip.

About Stokes Healthcare:

Stokes Pharmacy, a division of Stokes Healthcare, has been formulating custom prescription medications for both humans and animals since 1975. It has grown from a small hometown operation to a nationally respected compounding pharmacy. In 2018, Stokes Healthcare developed Epicur Pharma, an FDA-Registered 503B outsourcing facility, to serve the evolving needs of veterinary practices as regulations and laws changed, including GFI 256 and USP guidelines. Epicur manufactures standardized and tested bulk medications for hospital use following current Good Manufacturing Processes (cGMP). Each brand demonstrates Stokes' longstanding commitment to quality and improving patient outcomes with medication you trust. Learn more at www.stokespharmacy.com

About Bova:

The Bova Group comprises Bova Aus and Bova UK. Established in 1968 as a human pharmacy, Bova transitioned to veterinary compounding in 2010 under Nick Bova's leadership. By 2016, it had become the largest veterinary compounder in Australia, catering to numerous veterinarians nationwide. Bova Aus has implemented a robust quality assurance system for popular, high-risk, and complex compounded products in collaboration with the Australian Pesticides and Veterinary Medicines Authority (APVMA) to ensure compliance with prevailing regulations, adhering to USP or BP pharmacopoeia standards for quality control.

In 2017, Nick expanded operations to the UK with Bova UK, a Specials Manufacturer focused on delivering high-quality Specials Medications to the UK veterinary sector. Authorized by the Veterinary Medicines Directorate, the facilities obtained a Manufacturer 'Specials' Authorisation (ManSA) in 2017 for both sterile and non-sterile medicines. The company upholds stringent quality standards compliant with current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP) as outlined by the European Medicine Standards. For further information, please visit www.bova.vet.

Media Contact

Michael Tursi, Stokes Healthcare, 1 856-208-7811, [email protected], https://www.stokespharmacy.com/

SOURCE Stokes Healthcare

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.